Arrowhead Targets REDEMPLO Launch in 2027

Arrowhead Pharmaceuticals is aiming for a potential U.S. launch of its severe hypertriglyceridemia treatment, REDEMPLO, in the second quarter of 2027.

Updated on Nov. 13, 2026 in Healthcare

Bold flat-color editorial illustration of a single amber glass vial on a slate plinth beside rising clear droplets against a cream field, evoking a pending pharmaceutical approval.
Arrowhead Pharmaceuticals is targeting a second-quarter 2027 U.S. launch of REDEMPLO for severe hypertriglyceridemia, pending FDA approval, with a $3 billion to $4 billion sales opportunity. AI Illustration. Upload story photo >

Arrowhead Pharmaceuticals is targeting a potential U.S. launch of REDEMPLO, a treatment for severe hypertriglyceridemia, in the second quarter of 2027. FDA review and approval are still required before the product can launch.

Why it matters

The company reiterated a $3 billion to $4 billion U.S. sales opportunity for REDEMPLO, a figure that depends on the pending regulatory process. Early prescribing and insurance coverage signals give the launch plan additional context ahead of an FDA decision.

Arrowhead reported fiscal 2026 revenue of $450.82 million and a GAAP loss of $5.11 per share. The company has not yet provided sales guidance for REDEMPLO, and the $3 billion to $4 billion figure remains a stated opportunity rather than a forecast.

The players

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biotechnology company developing RNA-targeted medicines for metabolic and cardiovascular diseases.

The details

REDEMPLO is intended for severe hypertriglyceridemia. The FDA STAR pilot provides a six-month priority review framework for the application, and payer formularies have already covered more than 160 million U.S. lives for the product.

Timeline

  1. Fiscal 2026: Arrowhead reported its revenue and GAAP loss results.

  2. Q2 2027: Arrowhead targets a potential U.S. launch of REDEMPLO.

Market Landscape

The FDA STAR pilot's six-month priority review framework shapes how quickly REDEMPLO could reach the market. The approach places Arrowhead's launch timing within a faster regulatory track for a metabolic drug.

If approved, REDEMPLO would add a treatment option for people with severe hypertriglyceridemia. Availability will depend on FDA approval and on insurance formulary coverage, which already extends to more than 160 million U.S. lives.

The takeaway

Launch timing for REDEMPLO remains conditional on FDA review, so the 2027 target should be read as a plan rather than a confirmed date. Watch for regulatory updates before drawing conclusions about commercial potential.

Further reading

Explore more Healthcare coverage for context on drug approvals and launches.